malcolm mccoll

[ImmVirX @ImmVirX]

We're pleased to share that CEO & Co-Founder Dr Malcolm McColl will present at the @NWRcomms Virtual Healthcare Conference on Wednesday, 25 March, at 10:30am AEDT.

Interested parties are invited to register for the event at: https://t.co/oKD22lgiPS

[ImmVirX @ImmVirX]

Our team will be presenting two posters at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2026, taking place April 17-22 in San Diego: https://t.co/p6rhJCyFi1

[ImmVirX @ImmVirX]

Our Co-Founder and CSO Dr Darren Shafren recently presented an update on ImmVirX's clinical trial progress and future plans at the Bell Potter Securities Healthcare Conference.

Click here to view the presentation replay: https://t.co/zckWWA324Q

[ImmVirX @ImmVirX]

ImmVirX has expanded its clinical trial collaboration & supply agreement with Innovent into Hepatocellular Carcinoma, the most prevalent form of liver cancer: https://t.co/p05fR2c1xl

The companies will evaluate a combination therapy consisting of IVX037 & Innovent’s TYVYT®.

[malcolm mccoll @malcmccoll]

Great news as further strengthens our cash position as we advance our phase 1b with IVX037/ sintilimab in colorectal, gastric and ovarian cancer. https://t.co/yRe9yguKLs

[ImmVirX @ImmVirX]

CEO Dr Malcolm McColl joined the Phase III podcast to discuss ImmVirX’s oncolytic virus platform and its lead asset IVX037. Dr McColl describes IVX037’s mode of action, encouraging early clinical data and interest from pharma groups

Listen at: https://t.co/8bKQL2jO3d

[ImmVirX @ImmVirX]

ImmVirX today announced that the first 2 patients have been dosed in its CP-IVX001 Phase 1b trial: https://t.co/PWr1wgmqO5

The trial will evaluate IVX037 & Innovent Bio’s anti-PD-1 inhibitor TYVYT® (sintilimab) in patients with late stage colorectal, gastric and ovarian cancer.

[ImmVirX @ImmVirX]

ImmVirX has presented an update showing promising signals in its Phase 1a/b study targeting solid cancers at the MOGA Annual Meeting. IVX037 has been well tolerated, with signs of monotherapy activity, particularly in late-stage colorectal cancer patients: https://t.co/muoVkQYuah

[ImmVirX @ImmVirX]

ImmVirX is pleased to advise that Co-Founder and CEO Dr Malcolm McColl's presentation at The @Bell_Potter Healthcare Conference 2023 is now available.

Click here to view the presentation: https://t.co/invBU3NJkp

[ImmVirX @ImmVirX]

Delighted to welcome the @OneVenturesVC team, including our new Director Dr Jeannie Joughin, to our Newcastle laboratories to discuss & witness the exceptional progress across the clinical, preclinical & manufacture programs since the recent financing in May.

[ImmVirX @ImmVirX]

We're pleased to announce a $25m Series B funding round being led by renowned healthcare VC OneVentures.

“This is an outstanding result for the team at ImmVirX and for the unimpeded clinical development of our existing and planned programs"

Read more: https://t.co/djDfFtIDgO

[STARTUP DAILY @StartupDailyANZ]

Sydney VC VenturesOnes has pledged $15 million as a cornerstone investment towards a $25 million Series B raise for life sciences startup @ImmVirX.

https://t.co/98StBOsuhp

[ImmVirX @ImmVirX]

ImmVirX is pleased to announce the first patient has been dosed in its two-part Phase 1 clinical trial of oncolytic virus IVX037.

The Phase 1a part of the study will assess IVX037 in late stage colorectal, gastric or ovarian cancer patients.

Read more: https://t.co/sRVr7t608j

[ImmVirX @ImmVirX]

In case you missed it...

Yesterday our CEO Dr Malcolm McColl presented at the @NWRcomms Virtual Healthcare Conference, providing the latest updates on ImmVirX's progress toward the clinic.

The replay is now available to view: https://t.co/PRgmFVmykW

[American Cancer Society @AmericanCancer]

New report on colorectal cancer highlights the importance of cancer screenings: 1 in 5 people diagnosed are under 55 years old, a number that’s doubled since 1995. And, the number of people diagnosed with advanced-stage disease has increased significantly. https://t.co/zkbt2yLHfR

[ImmVirX @ImmVirX]

Looking at the healthcare sector for 2023, Australian Unity’s Victor Windeyer spoke to @alex_gluyas at @FinancialReview on his tips for the year:

“At the smaller end, I am bullish about ImmVirX... which is commencing first in-human clinical trials...”

https://t.co/PQIcIMozS0

[ImmVirX @ImmVirX]

We're pleased to share our CEO Dr Malcolm McColl presenting the ImmVirX story at the recent @Bell_Potter Healthcare Conference.

https://t.co/bvPeJCFwmf

[ImmVirX @ImmVirX]

With our first in human milestone approaching soon, our CEO Malcolm McColl & CSO Darren Shafren presented an update discussing lead candidate IVX037, the potential market opportunity, recent milestones achieved & what’s to come.

View the slides: https://t.co/4LYxyisHDV

[ImmVirX @ImmVirX]

"It is a credit to the team that we’ve continued to progress as expected and will soon hit our milestone of reaching the clinic with IVX037 on schedule.”

We're pleased to provide a summary of ImmVirX's operations for FY22. Read more: https://t.co/UIgIyks0DU

[ImmVirX @ImmVirX]

We were pleased to note in Merck’s most recently quarterly deck an update on CAVATAK (now V937) was provided. V937 was developed by the Viralytics team (now largely employed by ImmVirX) prior to its A$500 million acquisition by Merck in 2018.
Read more: https://t.co/Bzwe5VPHCW